The Novel Oral Typhoid Vaccine M01ZH09 Is Well Tolerated and Highly Immunogenic in 2 Vaccine Presentations | Zendy

Beth D. Kirkpatrick | Zendy; Katherine M. Tenney | Zendy; Catherine J. Larsson | Zendy; John P. O’Neill | Zendy; Cassandra H. Ventrone | Zendy; Matthew G. Bentley | Zendy; Anthony Upton | Zendy; Zoë Hindle | Zendy; Christine Fidler | Zendy; Deborah Kutzko | Zendy; Regan Holdridge | Zendy; Casey LaPointe | Zendy; Sandra Hamlet | Zendy; Steven N. Chatfield | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Novel Oral Typhoid Vaccine M01ZH09 Is Well Tolerated and Highly Immunogenic in 2 Vaccine Presentations

Author(s) -

Beth D. Kirkpatrick,

Katherine M. Tenney,

Catherine J. Larsson,

John P. O’Neill,

Cassandra H. Ventrone,

Matthew G. Bentley,

Anthony Upton,

Zoë Hindle,

Christine Fidler,

Deborah Kutzko,

Regan Holdridge,

Casey LaPointe,

Sandra Hamlet,

Steven N. Chatfield

Publication year - 2005

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/431605

Subject(s) - elispot , immunogenicity , medicine , typhoid fever , salmonella typhi , immunology , immune system , salmonella , vaccination , typhoid vaccine , virology , biology , t cell , escherichia coli , biochemistry , genetics , bacteria , gene

M01ZH09 (Salmonella enterica serovar Typhi [Ty2 aroC(-) ssaV(-)] ZH9) is a live oral-dose typhoid vaccine candidate. M01ZH09 was rationally modified with 2 independently attenuating mutations, including a novel mutation in Salmonella pathogenicity island (SPI)-2. We demonstrate that M01ZH09, in a single oral dose, is well tolerated and prompts broad immune responses, regardless of whether prevaccination with a bicarbonate buffer is given.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research